SY

Scott Young

Scott Young


Vice President



Professional Overview
Scott Young is an accomplished Vice President with extensive expertise in investor relations, corporate communications, and strategic business development. With a proven track record of driving growth and shareholder value, he specializes in navigating complex pharmaceutical and biotechnology environments.

Experience Summary

Current Role
As Vice President at Xilio Therapeutics, Inc., Scott is responsible for leading the company's investor relations and corporate communications strategies. He works closely with the executive team to facilitate transparent communication with the investment community, strengthen the company's public profile, and support the achievement of key business objectives.

Career Progression
Prior to his current role, Scott served as an Independent Investor Relations and Corporate Communications Executive at Autónomo, where he provided strategic counsel to life sciences companies. Before that, he held the position of Senior Vice President at Invivyd, where he spearheaded the company's successful initial public offering and ongoing investor relations initiatives.

Earlier in his career, Scott held Vice President roles in investor relations and corporate communications at Surface Oncology Inc. and Flexion Therapeutics, where he was instrumental in driving increased market awareness, securing strategic partnerships, and elevating the companies' profiles within the investment community.

Academic Background
Scott holds a Bachelor of Science degree in Business Administration from the University of Massachusetts Amherst, with a concentration in Finance and Marketing.

Areas of Expertise
  • Investor relations and corporate communications strategy

  • Pharmaceutical and biotechnology industry expertise

  • Capital markets and investor engagement

  • Strategic partnerships and business development

  • Crisis management and media relations

  • Leadership and team management


Professional Impact
During his tenure at Flexion Therapeutics, Scott played a pivotal role in the company's successful initial public offering, raising over $150 million in capital. He also led the development and implementation of innovative investor relations programs, which resulted in a significant increase in the company's shareholder base and improved market valuation.

At Surface Oncology Inc., Scott's strategic guidance and execution of the company's investor relations and corporate communications initiatives were instrumental in securing several high-profile collaborations with leading pharmaceutical firms, further strengthening the company's market position.

Conclusion
With his extensive experience, strategic vision, and proven track record of success, Scott Young is a valuable asset to Xilio Therapeutics, Inc. and the broader life sciences industry. His expertise in investor relations, corporate communications, and strategic business development positions him as a trusted advisor and a driving force behind the growth and success of the companies he serves.